28 July 2008

Lifeline Scientific, Inc
("Lifeline" or "the Company")

New Contract Win

Lifeline division wins contracts to supply LifePort Kidney Transporters To Carolina Donor Services

Lifeline Scientific, the medical technology company, announces that its Organ Recovery Systems division has won a contract for the sale of six LifePort® Kidney Transporters to Carolina Donor Services ("CDS"). CDS is one of the largest regional organ procurement organisations in the USA and serves a number of transplant centres in North Carolina, United States, including: North Carolina Baptist Hospital, Duke University, Pitt County, and the University of North Carolina.

The contract, which will also involve the sale of a significant volume of consumables and covers ongoing warranty and maintenance services. Based on historical data, it is expected that CDS will LifePort 225-250 kidneys annually.

David Kravitz, Chief Executive of Lifeline Scientific, said:

"This is the fifth significant contract we have announced since the completion of the IPO earlier this year and the subsequent commencement of the full commercial launch of the LifePort Kidney Transporter. Not only does LifePort help increase the number of available kidneys but also the quality of those organs, thus improving post-transplant outcomes for patients. LifePort is becoming an important tool in helping to reduce the continuing global shortage of organs for transplantation.

"The continued adoption of our LifePort Kidney Transporter as standard practice by prominent kidney transplant programmes gives us confidence for the future."

Enquiries

Lifeline Scientific, Inc.	
David Kravitz, CEO	
Seymour Pierce (Nomad)	**+44 (0)20 7107 8000**
Mark Percy / Huaizheng Peng / Sarah Jacobs	
Financial Dynamics	**+44 (0)20 7831 3113**
Ben Brewerton / John Dineen	

Notes to Editors

The LifePort Kidney Transporter is the Group's lead product. It is designed with the challenges of organ recovery and transport in mind, and provides a sealed, sterile, protected environment where a physiologic chemical solution is gently pumped through the donated kidney at cold temperatures to minimise tissue damage while the organ is outside the body.

Since receiving FDA clearance and CE Marking in 2004, over 250 LifePorts have been employed in pilot programs with leading transplant organizations throughout Europe and

North America, preserving more than 12,000 kidneys for clinical transplantation.

Initial clinical outcomes studies have shown that machine preservation improves the quality of a kidney from a cadaveric donor prior to transplantation in comparison to organs statically stored in a traditional cool box. This data demonstrates that machine perfused kidneys are more likely to function immediately after transplantation and remain healthier for longer. Results from an independent investigator driven multi-national, prospective, randomized clinical trial employing LifePort are expected to be published later this year.